Zipalertinib achieved a 30.2% intracranial objective response rate and 72.1% intracranial disease control rate in 43 evaluable patients with EGFR-mutated lung cancer and active CNS metastases. The Phase 2 findings support further development, although the treatment remains investigational.
Frontier Medicines will present its first Phase 1 clinical findings for FMC-376 at ESMO 2026, including preliminary responses in patients previously treated with KRAS G12C inhibitors. The investigational drug targets both active and inactive KRAS G12C, but detailed response rates and patient counts remain undisclosed ahead of the presentation.
A peer-reviewed validation study found that patients with high OncoPrism-NSCLC scores had a 71% response rate to checkpoint inhibitor-based treatment, compared with 36% in lower-scoring groups. The analysis included 1,487 patients across four datasets, although the prospective clinical utility of using the test to choose treatment remains unproven.
Verastem reports a 50% confirmed response rate in eight second-line pancreatic cancer patients receiving VS-7375, with a 41% rate across 22 previously treated patients at the selected 900 mg dose. The company is preparing a first-line Phase 3 study while pursuing broader development in lung and colorectal cancers.
Johnson & Johnson’s final PAPILLON analysis found median overall survival of 34.3 months with first-line RYBREVANT plus chemotherapy versus 27.9 months with chemotherapy, but the protocol-specified comparison was not statistically significant. With 76% of eligible chemotherapy patients later receiving amivantamab, the trial has become a case study in how effective crossover can obscure overall-survival differences.
Iovance approaches new lung cancer data as Amtagvi revenue hits $91 million and IOVA trades near a 52-week high after a major 2026 rally.
FDA clears Full-Life’s actinium-225 FL-261 for Phase 1 testing in c-MET-positive lung cancer as the radiopharmaceutical company expands its pipeline.
Global HARMONi data show ivonescimab plus chemotherapy reduced progression or death risk by 48% after third-generation EGFR-TKI failure, while overall survival had not reached statistical significance at the primary analysis.
Zipalertinib’s pivotal REZILIENT3 data will debut at WCLC 2026 after the first-line lung cancer trial met its PFS endpoint.
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.